Study To Examine Effect Of CP-866,087 On Consumption And Craving Of Alcohol In Alcohol Dependent Subjects.

Pfizer

Status and phase

Completed

Phase 2

Conditions

Alcoholism

Treatments

Drug: CP-866,087

Study type

Interventional

Funder types

Industry

Identifiers

NCT00147576

A5051005

Details and patient eligibility

About

Test the hypothesis that increasing doses of CP-866,087 will decrease the total number of drinks consumed during a 2 hour acute alcohol consumption assessment and to determine the safety and tolerability of multiple doses of CP-866,087 in alcohol dependent subjects compared to placebo.

Enrollment

88 patients

Sex

All

Ages

21 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subject meets the DSM-IV criterion for current alcohol dependence.
Subject is currently not engaged in, and does not want, treatment for alcohol related problems.

Exclusion criteria

Subject meets criteria for current DSM-IV diagnosis for any other psychoactive substance abuse or dependence disorder, excluding nicotine and caffeine.
Specialized inpatient or outpatient alcoholism or other addiction treatment (except nicotine) within the past 12 months.